Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. George Huntington
3. HD characteristics
4. The HD mutation and huntingtin protein
5. Htt protein
6. Cellular pathogenic pathways of Htt
7. HD is not just a disease of the basal ganglia
8. HD is more than a disease of the brain
9. Overview of our HD research at UCL
10. Delaying disease onset
11. Virtual explosion of HD recent research
12. What treatments are on the way
13. Novel therapies in or near trials
14. Promising preclinical targets in the pipeline
15. Understanding the disease in humans
16. HD clinical trials: challenges
17. Exploring for biomarkers at TRACKHD center
18. TRACKHD study design (1)
19. TRACKHD study design (2)
20. Published results in The Lancet Neurology
21. Baseline paper - 2009
22. Baseline imaging results
23. Baseline cognitive results
24. Baseline qMotor and oculomotor results
25. 12-months longitudinal analysis - January 2011
26. TRACK-HD premanifest A subject
27. 12-month imaging change
28. 12-month cognitive change (1)
29. 12-month cognitive change (2)
30. 12-month qMotor change
31. Analysis of 24 month observational data
32. 24-month change in whole brain atrophy
33. 24-month change in caudate volume
34. 24-month change in grey matter
35. 24-month change in white matter
36. Consistent change in early stage HD
37. Potential outcome measures for clinical trials
38. TRACK-HD 24-month effect sizes
39. Track-HD battery sample size estimates
40. Atrophy (1)
41. Atrophy (2)
42. Mutant HTT measured patients' WBCs
43. Mutant huntington fragmentation in immune cells
44. Mutant HTT in monocytes (1)
45. Mutant HTT in monocytes (2)
46. Study results - summary
47. When does neurodegeneration begin?
48. Timescale for brain changes
49. Challenges remaining
50. Hypotheses to test
51. Increased neural activity in premanifest HD
52. TrackOnHD - aims
53. The premanifest phase of neurodegeneration
54. Acknowledgements
55. The UCL ION HD team
56. Credits

Topics Covered

• Summary of the genetic, pathophysiology and clinical features of Huntington's disease
• Potential drug targets in development for Huntington's disease
• The importance of biomarkers in Huntington's disease
• Current biomarkers in development in Huntington's disease

Links

Series:

• Biomarkers

Categories:

• Clinical Practice
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Tabrizi, S. (2013, February 28). Biomarkers for Huntington's disease - promises and challenges [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/VLTS6044.
Export Citation (RIS)

Publication History

• Published on February 28, 2013

Financial Disclosures

• Prof. Sarah Tabrizi has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.